|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsored by: |
National Heart, Lung, and Blood Institute (NHLBI) |
| Information provided by: | National Heart, Lung, and Blood Institute (NHLBI) |
| ClinicalTrials.gov Identifier: | NCT00000484 |
Purpose
To determine whether the long-term treatment of essential hypertension without significant target organ disease materially influenced mortality and/or cardiovascular renal morbidity.
| Condition | Intervention | Phase |
|
Cardiovascular Diseases Heart Diseases Hypertension Vascular Diseases |
Drug: chlorothiazide Drug: Rauwolfia alkaloids |
Phase III |
| MedlinePlus related topics: | Heart Diseases High Blood Pressure Vascular Diseases |
| Drug Information available for: | Chlorothiazide Chlorothiazide sodium Alkaloids, Rauwolfia |
| Study Type: | Interventional |
| Study Design: | Prevention, Randomized, Double-Blind, Placebo Control |
| Study Start Date: | April 1966 |
BACKGROUND:
This grant-supported, cooperative, fixed-protocol clinical study was initiated in 1966 and followed a cooperative study of the treatment of renal hypertension initiated in 1960 to evaluate the relative efficacy of several recognized drug regimens for reduction of blood pressure. Six centers (USPHS hospitals) and a coordinating center were involved in the trial.
DESIGN NARRATIVE:
Randomized, double-blind, fixed sample. Three hundred and eighty nine eligible patients were assigned to drug therapy consisting of chlorothiazide plus Rauwolfia serpentina or to placebo.
Eligibility
| Ages Eligible for Study: | 21 Years to 55 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Men and women, ages 21-55. Mild essential hypertension (diastolic blood pressure over 90 mm Hg.
Contacts and Locations| Investigator: | Anthony Damato | USPHS Hospital |
| Investigator: | Richard Thurm | USPHS Hospital |
| Investigator: | Christfried Urner | USPHS Hospital |
| Investigator: | John Vaillancourt | USPHS Hospital |
| Investigator: | J. Warbasse | USPHS Hospital |
| Investigator: | Robert Wells | USPHS Hospital |
More Information
|
[No authors listed] Morbidity and mortality in mild essential hypertension. Circ Res. 1972 Sep;31(9):Suppl 2:110-24. No abstract available.
  |
|
U.S. Public Health Service Hospitals Cooperative Study Group. Smith WM, et al: Intervention Trial in Mild Hypertension. Epidemiology and Control of Hypertension. Paul, O (Ed.), Symposia Specialists, Miami, l975, pp. 46l-483.
  |
|
Elharrar V, Foster PR, Jirak TL, Gaum WE, Zipes DP. Alterations in canine myocardial excitability during ischemia. Circ Res. 1977 Jan;40(1):98-105.
  |
|
Smith WM. Mild essential hypertension: benefit of treatment: discussion. Ann N Y Acad Sci. 1978 Mar 30;304:74-80. No abstract available.
  |
|
Smith WM, Edlavitch SA, and Krushat WM: U.S. Public Health Service Hospitals Intervention Trial in Mild Hypertension. Hypertension, Determinants, Complications, and Intervention. Onesti G, and Klimt C, (Eds.), Grune & Stratton, New York, l979, pp. 38l-399.
  |
|
Smith WM: Hypertension--Effectiveness of Early Treatment in Preventing Sequellae. Proceedings of the Eisenhower Medical Center. Preventive Interventions in the Practice of Medicine, Spring, l979, pp. 8l-87.
  |
|
Smith WM, Edlavitch SA, and Krushat WM: Prevention of Stroke in Mild Hypertension: Public Health Service Hospitals Trial. Perspectives in Cardiovascular Research, Vol. 4. Prophylactic Approach to Hypertensive Diseases, Yamori Y, Lovenberg W, and Freis ED, (Eds.), Raven Press, New York, l979, pp. 53-62.
  |
| Study ID Numbers: | 3 |
| First Received: | October 27, 1999 |
| Last Updated: | June 23, 2005 |
| ClinicalTrials.gov Identifier: | NCT00000484 |
| Health Authority: | United States: Federal Government |
|
|
|